Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Brief Summary: Lentigo malignant (LM) is an intraepidermal melanocytic proliferation occurring on photoexposed skin. In our project, this term applies both to Dubreuilh's melanosis and to Dubreuilh's intraepidermal melanoma. It consequently excludes invasive melanoma. Although surgery is the treatment of choice, it remains without consensus on the margins (5 mm or 10 mm) excision for a localized tumor on the face.

Several studies have shown that imiquimod, activating local immunity by interferon production, induced LM or MLM regression and could also decrease the frequency of relapses.

The principal aim of our project is to study the effect of imiquimod versus placebo in pre-operative neoadjuvant treatment aimed at reducing both surgical margins, as from the first surgical procedure, and the frequency of short and medium term recurrence of LM. Furthermore, the improvement in patient quality of life could also be significant.


Options:
A: Arm Label: Imiquimod; Type: EXPERIMENTAL; Interventions: Drug: Imiquimod cream + surgery | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + surgery | Intervention Type: DRUG; Name: Imiquimod cream + surgery; Assigned to Arm(s): Imiquimod | Intervention Type: DRUG; Name: Placebo + surgery; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: Domatinostat; Assigned to Arm(s): B, C, D | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): A, B, C, D | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): D
C: Arm Label: GSK1120212; Type: EXPERIMENTAL; Interventions: Drug: GSK1120212 | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK1120212 | Intervention Type: DRUG; Name: GSK1120212; Assigned to Arm(s): Crossover, GSK1120212 | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy
D: Arm Label: Arm I (sargramostim, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Biological: Tyrosinase Peptide | Arm Label: Arm II (sargramostim placebo, peptide vaccine); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Tyrosinase Peptide | Arm Label: Arm III (sargramostim, peptide placebo); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo, Biological: Sargramostim | Arm Label: Arm IV (placebo, peptide placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Arm Label: Arm V (sargramostim); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Sargramostim | Arm Label: Arm VI (sargramostim placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo), Arm V (sargramostim), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (sargramostim placebo, peptide vaccine), Arm IV (placebo, peptide placebo), Arm VI (sargramostim placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm III (sargramostim, peptide placebo), Arm IV (placebo, peptide placebo) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm III (sargramostim, peptide placebo), Arm V (sargramostim) | Intervention Type: BIOLOGICAL; Name: Tyrosinase Peptide; Assigned to Arm(s): Arm I (sargramostim, peptide vaccine), Arm II (sargramostim placebo, peptide vaccine)

Answer: A